Literature DB >> 7720740

Genetic counselling on brittle grounds: recurring osteogenesis imperfecta due to parental mosaicism for a dominant mutation.

M Raghunath1, K Mackay, R Dalgleish, B Steinmann.   

Abstract

UNLABELLED: Osteogenesis imperfecta (OI), a dominantly inherited connective tissue disorder, is usually caused by defects in collagen I. There is growing evidence for parental mosaicism that results in affected children born to unaffected parents. This situation poses a difficult task for the geneticist because a mosaic parent may appear clinically healthy while carrying the mutation in a fraction of her or his gonadal cells. To illustrate this problem, we report a Swiss couple whose first child was affected with severe OI. The unexpected recurrence of the disorder in the second child raised the suspicion of a recessive trait or, rather, of parental mosaicism. We identified the responsible collagen mutation in the COL1A2 gene (Gly688Ser in the alpha 2(I)-chain) in both children and demonstrated the father to be a somatic mosaic for this mutation and to have subtle clinical signs such as soft skin and short stature that may be a result of his mosaic state.
CONCLUSION: After the birth of a child affected with OI the possibility of parental mosaicism should be considered and options for prenatal diagnosis discussed.

Entities:  

Mesh:

Year:  1995        PMID: 7720740     DOI: 10.1007/bf01991915

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  A dominant mutation in the COL1A1 gene that substitutes glycine for valine causes recurrent lethal osteogenesis imperfecta.

Authors:  J Bonaventure; L Cohen-Solal; C Lasselin; P Maroteaux
Journal:  Hum Genet       Date:  1992-08       Impact factor: 4.132

Review 2.  Review and hypotheses: somatic mosaicism: observations related to clinical genetics.

Authors:  J G Hall
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

3.  Variable expression of osteogenesis imperfecta in a nuclear family is explained by somatic mosaicism for a lethal point mutation in the alpha 1(I) gene (COL1A1) of type I collagen in a parent.

Authors:  G A Wallis; B J Starman; A B Zinn; P H Byers
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

4.  Impaired secretion of type III procollagen in Ehlers-Danlos syndrome type IV fibroblasts: correction of the defect by incubation at reduced temperature and demonstration of subtle alterations in the triple-helical region of the molecule.

Authors:  A Superti-Furga; B Steinmann
Journal:  Biochem Biophys Res Commun       Date:  1988-01-15       Impact factor: 3.575

5.  Phenotypic heterogeneity in osteogenesis imperfecta: the mildly affected mother of a proband with a lethal variant has the same mutation substituting cysteine for alpha 1-glycine 904 in a type I procollagen gene (COL1A1).

Authors:  C D Constantinou; M Pack; S B Young; D J Prockop
Journal:  Am J Hum Genet       Date:  1990-10       Impact factor: 11.025

6.  Prenatal diagnosis of collagen disorders by direct biochemical analysis of chorionic villus biopsies.

Authors:  M Raghunath; B Steinmann; C Delozier-Blanchet; P Extermann; A Superti-Furga
Journal:  Pediatr Res       Date:  1994-10       Impact factor: 3.756

7.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

8.  Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible.

Authors:  G A Wallis; B Sykes; P H Byers; C G Mathew; D Viljoen; P Beighton
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

9.  Somatic cell mosaicism: another source of phenotypic heterogeneity in nuclear families with osteogenesis imperfecta.

Authors:  C D Constantinou-Deltas; R L Ladda; D J Prockop
Journal:  Am J Med Genet       Date:  1993-01-15

10.  Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a mutation in the COL1A2 gene of type I collagen. The mosaic parent exhibits phenotypic features of a mild form of the disease.

Authors:  M J Edwards; R J Wenstrup; P H Byers; D H Cohn
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

View more
  9 in total

1.  Discordant segregation of Xq28 markers and a mutation in the L1 gene in a family with X linked hydrocephalus.

Authors:  M Jouet; L Strain; D Bonthron; S Kenwrick
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

2.  Clinical signs of mosaicism.

Authors:  K Méhes; G Kosztolányi
Journal:  Eur J Pediatr       Date:  1995-08       Impact factor: 3.183

3.  Substitution of glycine-661 by serine in the alpha1(I) and alpha2(I) chains of type I collagen results in different clinical and biochemical phenotypes.

Authors:  L Nuytinck; R Dalgleish; L Spotila; J P Renard; N Van Regemorter; A De Paepe
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

4.  Gonadal mosaicism and familial adenomatous polyposis.

Authors:  Angela L Schwab; Thérèse M F Tuohy; Michelle Condie; Deborah W Neklason; Randall W Burt
Journal:  Fam Cancer       Date:  2007-11-18       Impact factor: 2.375

5.  A Gly238Ser substitution in the alpha 2 chain of type I collagen results in osteogenesis imperfecta type III.

Authors:  N J Rose; K Mackay; P H Byers; R Dalgleish
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

Review 6.  A Case Based Approach to Clinical Genetics of Thoracic Aortic Aneurysm/Dissection.

Authors:  Betti Giusti; Stefano Nistri; Elena Sticchi; Rosina De Cario; Rosanna Abbate; Gian Franco Gensini; Guglielmina Pepe
Journal:  Biomed Res Int       Date:  2016-05-25       Impact factor: 3.411

7.  Asymptomatic parental mosaicism for osteogenesis imperfecta associated with a new splice site mutation in COL1A2.

Authors:  Anja Lisbeth Frederiksen; Morten Duno; Iben B G Johnsen; Morten Frost Nielsen; Anne Bruun Krøigård
Journal:  Clin Case Rep       Date:  2016-08-31

8.  [Osteogenesis imperfecta: report of a case].

Authors:  Najeh Hsayaoui; Chaouki Mbarki; Saoussen Melliti; Youssef El Cadhi; Fatma Douik; Sana Mezghanni; Hedhili Oueslati
Journal:  Pan Afr Med J       Date:  2015-06-03

9.  Allele dependent silencing of collagen type I using small interfering RNAs targeting 3'UTR Indels - a novel therapeutic approach in osteogenesis imperfecta.

Authors:  Katarina Lindahl; Andreas Kindmark; Navya Laxman; Eva Åström; Carl-Johan Rubin; Östen Ljunggren
Journal:  Int J Med Sci       Date:  2013-08-13       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.